Veracyte (FRA:12V) Current Deferred Revenue : €1.6 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Veracyte's current deferred revenue for the quarter that ended in Mar. 2025 was €1.6 Mil.

Veracyte Current Deferred Revenue Historical Data

The historical data trend for Veracyte's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Current Deferred Revenue Chart

Veracyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

0.31

4.11

2.47

1.84

1.60

Veracyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Deferred Revenue	Get a 7-Day Free Trial															2.39	2.04	1.83	1.60	1.58

Veracyte Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Veracyte's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

VCYT:USA

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Veracyte Headlines

No Headlines